GlassScriptPhysician profile
Lenny M Cohen
NPI 1730397878
$21,313.35
in general payments reported to CMS, 2019-2025
49 companies · $3,104 in 2025
The $3,104 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $2,640 · 2021: $4,657 · 2022: $2,557 · 2023: $2,125 · 2024: $3,969 · 2025: $3,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,048 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,047.52 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,036.20 | 2020-2021 | |
| Biogen, INC. | $2,657.77 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Abbvie INC. | $2,070.24 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Brainsway USA INC | $1,675.11 | 2024-2025 | Brainsway Deep Tms System, Deep Tms System |
| Teva Pharmaceuticals USA, INC. | $1,008.11 | 2019-2023 | Ajovy |
| Pfizer INC. | $975.60 | 2023-2025 | |
| Lilly USA, LLC | $945.90 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Emd Serono, INC. | $945.67 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $797.82 | 2019-2025 | |
| Amgen INC. | $772.50 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $552.80 | 2019-2024 | Soliris |
| Genzyme Corporation | $546.78 | 2019-2025 | |
| Tg Therapeutics, INC. | $546.02 | 2023-2025 | |
| Genentech USA, INC. | $483.77 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Upsher-Smith Laboratories LLC | $458.24 | 2020-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenny Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.